More good news. For egg-based (but not cellular based) flu vaccine manufacturers, the current flu vaccine is as I had said before already obsolete and off target (the one we in the USA are taking right now.) A change for 2018 for the next Southern Hemisphere vaccine is in the works-too late for all of us. From CIDRAP:
WHO swaps out H3N2, B strains in Southern Hemisphere flu vaccine
Filed Under: http://www.cidrap.umn.edu/infectious-disease-topics/influenza-vaccines" rel="nofollow - Influenza Vaccines ; http://www.cidrap.umn.edu/infectious-disease-topics/influenza-general" rel="nofollow - Influenza, General http://www.cidrap.umn.edu/ongoing-programs/news-publishing/news-publishing-staff" rel="nofollow - Lisa Schnirring | News Editor | CIDRAP News |
http://www.cidrap.umn.edu/file/glovedhandandvialjpg-0" rel="nofollow - gloved_hand_and_vial.jpg
At
their meeting this week in Melbourne, Australia, World Health
Organization (WHO) vaccine advisors today recommended changing two of
three components for trivalent vaccines that pharmaceutical companies
will produce for the Southern Hemisphere's 2018 flu season. The
group recommended a new influenza A H3N2 strain, and swapped out the
Victoria-lineage B strain with a Yamagata-lineage virus that had been
recommended last year as the second B strain in quadrivalent vaccine
formulations. The WHO recommends the following for the Southern Hemisphere's trivalent vaccines: - For H1N1, an A/Michigan/45/2015-like virus
- For H3N2, an A/Singapore/INFIMH-16-0019/2016-like virus
- For B, a Phuket/3073/2013-like virus (belonging to the Yamagata lineage)
For
quadrivalent vaccines that contain two influenza B strains, WHO experts
recommend adding Brisbane/60/2008-like virus, a Victoria-lineage virus
what was a component of trivalent versions of the Southern Hemisphere's
current vaccine as well as the Northern Hemisphere's 2017-18 season
vaccines. Seasonal flu vaccines for the Northern Hemisphere's flu
season will still contain the earlier H3N2 strain, and its trivalent
vaccine's B strain will be the Victoria-lineage virus. Changes in circulating H3N2 virusesAt
the global level, H3N2 and influenza B are the predominant seasonal flu
strains, and in the most recent flu developments, Australia is still
reporting high flu levels, led by H3N2, with high numbers of deaths in
nursing homes and in healthy adults. Australia's Department of
Health said in a statement yesterday that overall, the 2017 vaccines
have been a "relatively good" match, but evidence suggests less
effectiveness than usual, especially for protecting seniors against H3N2
infection. In its strain selection report, the WHO said the
majority of H3N2 strains that circulated from February to September
belonged to the clade 3C.2a and subclade 3C.2.a1, which continue to show
considerable diversity in their hemagglutinin and neuraminidase genes. Most
recent viruses are antigenically similar to the cell-propagated version
of Hong Kong vaccine virus from the previous season, but were less
similar to the egg-propagated virus, according to results from ferret
serum tests. Ferret serum tests showed that circulating strains
were better inhibited by antibodies raised against the egg-propagated
Singapore H3N2 vaccine virus strain. The group also said the Singapore
vaccine strain, part of the 3C.2.a1 subclade, contains the N121K
hemagglutinin substitution seen in the majority of recent H3N2 viruses
and that the neuraminidases of recent H3N2 viruses are antigenically
distinct from last season's H3N2 vaccine component. Dan Jernigan,
MD, MPH, with the US Centers for Disease Control and Prevention's
National Center for Immunization and Respiratory Diseases, was asked
about the WHO's new H3N2 component recommendation today at an annual
news briefing hosted by the National Foundation for Infectious Diseases
(NFID) to raise awareness about seasonal flu vaccination. He said there
has been a little bit of drift in circulating H3N2 strains but no
significant mutation. Jernigan said the new vaccine strain mainly
affects egg-based flu vaccine manufacturers. Regarding influenza
B, both lineages co-circulated in varying proportions in different
regions, but Yamagata predominated in Oceana, Europe, and the Americas,
with Victoria more common in Asia and Africa.
------------- John L.
|